Stock Evaluator: BlossomHill Therapeutics, Inc. (BLSM)
BlossomHill Therapeutics, Inc. BLSM
$22.01
1.99
9.94%
September 4, 2026 4:00:00 PM
EST
Volume: 168,701
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.
Financial Summary
| Share Statistics | BLSM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $674.5 | $674.5 | 40% |
|
| Shares Out (Mil) | 2.6 | 43.5 | 9% |
|
| Institutional Ownership | 40.6% | 84.6% | 17% |
|
| Float (Mil) | 16.6 | 47.3 | 26% |
|
| Beta | na | 0.71 | na |
|
| Avg Daily Volume (000s) | 129 | 290 | 40% |
|
| Price Change (52-week) |
na | 69.3% | na |
|
| Growth | BLSM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | na | (1.4%) | na |
|
| EPS (5yr) | na | 15.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.0%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | BLSM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $317 | na |
|
| Net Income (TTM) (Mil) | ($71) | ($11) | 13% |
|
| EPS (TTM) | ($28.585) | ($0.700) | 2% |
|
| Operating Cash Flow (TTM) (Mil) | ($57) | ($6) | 9% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $23 | $6 | 33% |
|
| Enterprise Value (Q1) (Mil) | $659 | $536 | 36% |
|
| Valuation | BLSM | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.80 | na |
|
| P/E | na | 17.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | BLSM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.1% | na |
|
| Net Margin | na | (1.4%) | na |
|
| ROA | (99.1%) | (24.1%) | 6% |
|
| ROE | 93.5% | (21.0%) | 96% |
|
| Liabilities to Assets | 27.0% | 32.3% | 19% |
|
| F-Score | 1 | 3 | na |
|
BlossomHill Therapeutics, Inc. did not pass any screens on 9/4/2026.
